The positive results from the Phase III study of tradipitant indicate that the drug is effective in preventing vomiting associated with motion sickness. This is likely to have a positive impact on Vanda Pharmaceuticals' stock price in the short term, as it demonstrates the potential for future revenue generation from the drug. The company's plans to pursue FDA approval also signal confidence in the drug's efficacy and safety, which could further boost investor sentiment.